LGV is thought to account for 2 -10% of genitoulcerative disease in areas such as India and Africa. In Western regions LGV is endemic among MSM, mainly those co-infected with HIV. 2, 3 Heterosexual transmission has been described recently in Spain 4 and Portugal; 5 † Neither the degree of infectiousness nor the reservoir of disease has been accurately defined, but heterosexual transmission has been attributed largely to asymptomatic female carriers and in the MSM population, asymptomatic or unrecognized rectal infection is the likely source of onward transmission. 3 
CLINICAL FEATURES
The disease course usually follows three separate stages.
(1) Primary stage † Incubation period -one to four weeks; 10 † In the current LGV epidemic among MSM, proctitis is the primary manifestation of infection, usually presenting within a few weeks of sexual contact. It is characterized by severe symptoms of anorectal pain, haemopurulent discharge and bleeding per rectum; tenesmus and constipation are also seen due to the mucosal and perirectal oedema. Proctoscopic examination may reveal a distal granular or haemorrhagic proctitis with purulent exudate and mucosal ulceration.
LGV proctitis is not usually accompanied by inguinofemoral lymphadenopathy; however, radiological imaging may demonstrate pelvic node involvement; 6 † In the present LGV epidemic among MSM, symptomatology has varied in different populations, with UK cohorts showing almost all LGV to be symptomatic, 7 in contrast to Dutch studies where a significant proportion of asymptomatic infection has been detected; 8,9 † LGV proctitis mimics chronic inflammatory bowel diseases like Crohn's disease, both clinically and histopathologically; 10 † A primary lesion may be evident -a small painless papule or pustule; this can erode to form a small herpetiform ulcer. It usually heals within one week and often remains unnoticed. Mucopurulent discharge may be present, affecting the urethra, the cervix or the rectum depending on the inoculation site; (2) Second stage or 'inguinal stage' -begins two to six weeks after onset of primary lesion. Causes painful inflammation of the inguinal and/or femoral lymph nodes. Typically this produces unilateral enlargement, inflammation, suppuration and abscesses. These 'buboes' may become fluctuant and rupture in one-third of patients. Some patients develop the 'groove sign', which results from enlargement of the inguinal nodes above and the femoral nodes below Poupart's ligament; women more often have primary involvement of the rectum, upper vagina, cervix or urethra; as these regions drain to the deep iliac or perirectal nodes, inguinofemoral lymphadenopathy is not seen. The resultant intraabdominal or retroperitoneal lymphadenopathy may lead to symptoms of lower abdominal pain or low back pain; † Constitutional symptoms, such as low-grade fever, chills, malaise, myalgias and arthralgias, may present during the second stage of disease. In addition, systemic spread of C. trachomatis occasionally results in arthritis, pneumonitis or (peri) hepatitis. Rare systemic complications include cardiac involvement, aseptic meningitis and ocular inflammatory disease; † A rare presentation is the pharyngeal syndrome affecting the mouth and throat. Cervical lymphadenopathy and buboes can occur; 11 (3) Third stage, often called the 'anogenitorectal syndrome'. It is more often present in women. Patients initially develop proctocolitis followed by peri-rectal abscess, fistulas, strictures and stenosis of the rectum, possibly leading to 'lymphorrhoids' (haemorrhoid-like swellings of obstructed rectal lymphatic tissue). Without treatment, chronic progressive lymphangitis leads to chronic oedema and sclerosing fibrosis, resulting in strictures and fistulas of the involved region, which can ultimately lead to elephantiasis, esthiomene (the chronic ulcerative disease of the external female genitalia) and the frozen pelvis syndrome. If left untreated, LGV proctitis can lead to rectal stricture, with subsequent sequelae of soiling, pain, constipation and the possible development of mega colon. 12 
DIAGNOSIS
The diagnosis of LGV is confirmed by the detection of biovarspecific C. trachomatis DNA in: (1) ulcer material from primary anogenital lesions; (2) rectal specimens (in suspected cases of anorectal LGV) -anorectal swabs are preferably collected from the mucosal lining under proctoscopic vision, alternatively a blind anorectal swab can suffice; or (3) bubo aspirates (in suspected cases of inguinal LGV) -historically, LGV has been difficult to isolate from bubo aspirates in culture studies (see Appendix B: IV, C). Modern diagnostic approaches have been reviewed recently 9 and most modern laboratories follow a two-step procedure: † First, a commercially available C. trachomatis nucleic acid amplification test (NAAT) can be used to screen suspected samples. Although commercially available tests are not approved for extragenital sites, a large body of literature supports the use of these tests for the detection of rectal chlamydial infections 9,13 -15 (see Appendix B: III, B); † If C. trachomatis is detected, LGV biovar-specific DNA then needs to be detected from the same specimen. For this purpose, two 'in house' NAATs have been reported; firstly, a real-time PCR-based test that specifically detects all C. trachomatis LGV biovar strains 16 and, more recently, a realtime quadriplex PCR-based assay, which incorporates both
LGV-specific and non-LGV-specific target sequences, a C. trachomatis plasmid target and the human RNase P gene as an internal control 17 (see Appendix B: III, B).
If molecular diagnostic test facilities are not available, then a presumptive LGV diagnosis can be made using chlamydia genus-specific serological assays. A high antibody titre (esp. IgA anti-major outer membrane protein [MOMP] antibodies) in a patient with a clinical syndrome suggestive of LGV supports the diagnosis. 18, 19 Nonetheless, a low titre does not exclude LGV, nor does a high titre in a patient without LGV symptomatology confirm LGV infection 8, 9 (see Appendix B: III, B).
MANAGEMENT
As the rectum is the most common site for the detection of C. trachomatis in MSM 20 
THERAPY
Despite a paucity of robust evidence 21 regarding the efficacy of therapy for any rectal chlamydial infections (LGV or non-LGV), current guidelines recommend three weeks of oral doxycycline 100 mg twice daily to treat LGV 22 -24 and the vast majority of recent MSM case reports have observed complete responses to this therapy; shorter courses may not eradicate the organism. 25 
